Local Chapter of National Office Property Association
Awards New MedImmune Facility in Gaithersburg
GAITHERSBURG, Md., June 23 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that the Maryland/DC National Association of
Industrial and Office Properties has bestowed honors on the company's new
facility in Gaithersburg. The company's newly completed state-of-the-art
research and development facility and worldwide corporate headquarters was
recognized for "Best Biotech Office" and "Best Interiors - Commercial Space"
at the association's 2nd Annual Awards of Excellence program held May 13, 2004
in Washington, DC. The program is designed to honor superior performance in
commercial and industrial real estate.
David M. Mott, MedImmune's president and chief executive officer, stated:
"As MedImmune has grown over the years, so has our need for expanded
facilities that can keep pace with our continuing progress. The new building
confirms our commitment to excellence in science and medicine by placing our
research functions at its core."
MedImmune's relocation to the building in March 2004 marked the completion
of the first of three phases of construction. Designed by HOK Architects, the
approximately $88 million building sits on a 22-acre property on Great Seneca
Highway in Gaithersburg, Maryland and presently houses more than 600
employees. When fully expanded, the facility may encompass 750,000 square
feet and have the capacity for 2,200 employees.
To celebrate the grand opening and recent awards, MedImmune will welcome
employees and their families to an Open House on Saturday, June 26. The Open
House will feature activities for children, and visitors will have the
opportunity to take guided tours highlighting the building's amenities and
showcasing the innovative research and development performed by MedImmune
researchers. In July, Maryland Governor Robert Ehrlich is expected to perform
the official ribbon-cutting for the new facility at a reception for local
government and business leaders.
About MedImmune, Inc.
MedImmune is a leading biotechnology company focused on researching,
developing and commercializing products to prevent or treat infectious
disease, autoimmune disease and cancer. MedImmune actively markets four
products, Synagis(R) (palivizumab), Ethyol(R) (amifostine), FluMist(TM)
(Influenza Virus Vaccine Live, Intranasal), and CytoGam(R) (cytomegalovirus
immune globulin intravenous (human)), and has additional products in clinical
testing. MedImmune employs approximately 1,800 people, is headquartered in
Gaithersburg, Maryland, and has additional operations in Frederick, Maryland,
as well as Pennsylvania, California, Kentucky, the United Kingdom and the
Netherlands. For more information on MedImmune and its products, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.
/CONTACT: Media: Jamie Lacey, +1-301-398-4035; or Investors: Peter Vozzo,
+1-301-398-4358, or John Filler, +1-301-398-4086, all of MedImmune, Inc./
/Web site: http://www.medimmune.com /
CO: MedImmune, Inc.; National Association of Industrial and Office Properties
IN: HEA MTC BIO RLT
-- DCW024 --
4241 06/23/2004 11:01 EDT http://www.prnewswire.com